Don't Just Read the News, Understand It.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Eid
Elon Musk
Donald Trump
World Cup
Social Media
NBA
Artificial Intelligence
Soccer
Tesla
Housing
Education
Baseball
Published • loading... • Updated

Bispecific competition, debating oral SERDs and a bold GLP-1 prediction

Summary by biopharmadive.com
Antibody drugs that target the PD-1 and VEGF pathways are in the ASCO spotlight, while doctors wrestle with how to use a new crop of breast cancer medicines.

1 Articles

All
Left
Center
1
Right
biopharmadive.combiopharmadive.com
Center

Bispecific competition, debating oral SERDs and a bold GLP-1 prediction

Antibody drugs that target the PD-1 and VEGF pathways are in the ASCO spotlight, while doctors wrestle with how to use a new crop of breast cancer medicines.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

biopharmadive.com broke the news in on Monday, June 2, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Breast Cancer

Breast Cancer

News
For You
SearchBlindspotLocal